Advertisement

Tumor Biology

, Volume 34, Issue 5, pp 2633–2643 | Cite as

DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma

  • Cailing Yang
  • Dapeng Wu
  • Jinling Jia
  • Dong Liu
  • Zhanguo Li
  • Chunxiao Zhang
  • Min Li
  • Yonghua Xia
Research Article

Abstract

Increasing evidence has demonstrated that the tumor suppressor gene deleted in liver cancer-1 (DLC1) is tightly implicated in the development and progression of tumors and is verified to be downregulated in a variety of tumors. However, the roles and precise molecular mechanisms of DLC1 in cutaneous squamous cell carcinoma (cutaneous SCC) remain to be elucidated. In the present study, we confirmed the reduced level in cutaneous SCC tissues and cells, and DLC1 mRNA relative level in cutaneous SCC tissues with lymph node metastasis (0.801 ± 0.079) was markedly lower than those without lymph node metastasis (1.245 ± 0.071) (P < 0.0001). Importantly, the survival rates of patients with low DLC1 level were lower than those with high DLC1 level (P = 0.0051). Further investigation revealed that DLC1 overexpression inhibited proliferation and arrested cell cycle at G0/G1 phase in A431 cells, which may be tightly associated with upregulation of p21 protein and downregulation of cyclin D1 and cdk2 proteins. Moreover, the decreases of FAK and p-FAK as well as the increase of E-cadherin level mediated by elevated DLC1 level suppressed invasion in A431 cells. Additionally, DLC1 overexpression induced apoptosis coupled with elevations of Bax level and caspase-3 activity and decrease of Bcl-2 level in A431 cells. Taken altogether, our data presented herein suggest that DLC1 plays a pivotal role in the development and progression of cutaneous SCC, which may be in part achieved by regulating the signaling pathway related to proliferation, invasion, cell cycle, and apoptosis in cutaneous SCC cells.

Keywords

Cutaneous squamous cell carcinoma Deleted in liver cancer-1 Invasion Cell cycle Apoptosis 

Notes

Acknowledgments

This work was supported by Grant of a Research Contact with the Education Bureau of Henan Province (no. 2011A320017).

References

  1. 1.
    Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115(5):870–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327(23):1649–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.CrossRefPubMedGoogle Scholar
  4. 4.
    McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol. 2009;30(2):121–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? Dermatol Surg. 2007;33(4):410–20.PubMedGoogle Scholar
  6. 6.
    Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33(8):885–99.PubMedGoogle Scholar
  7. 7.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Joseph AK, Mark TL, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol Surg. 2001;27(11):955–9.PubMedGoogle Scholar
  9. 9.
    Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84(4):235–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998;58(10):2196–9.PubMedGoogle Scholar
  11. 11.
    Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol. 2003;129(6):349–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, et al. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 2003;22(3):445–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Tripathi V, Popescu NC, Zimonjic DB: DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Oncogene 2013. doi: 10.1038/onc.2013.7.
  14. 14.
    Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res. 2006;12(5):1412–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene. 2003;22(25):3943–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 2004;23(7):1405–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 2007;26(6):934–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Tripathi SC, Kaur J, Matta A, Gao X, Sun B, Chauhan SS, et al. Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma. Mod Pathol. 2012;25(1):14–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Wu PP, Jin YL, Shang YF, Jin Z, Wu P, Huang PL. Restoration of DLC1 gene inhibits proliferation and migration of human colon cancer HT29 cells. Ann Clin Lab Sci. 2009;39(3):263–9.PubMedGoogle Scholar
  20. 20.
    Zhang T, Zheng J, Liu C, Lu Y. Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int. 2009;82(4):380–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang T, Zheng J, Jiang N, Wang G, Shi Q, Liu C, et al. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma. Cancer Lett. 2009;283(1):59–67.CrossRefPubMedGoogle Scholar
  22. 22.
    Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, et al. Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery. 2008;63(4):771–80. discussion 780–771.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME, Popescu NC. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol. 2008;32(6):1285–91.PubMedGoogle Scholar
  24. 24.
    Feng M, Huang B, Du Z, Xu X, Chen Z. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep. 2011;38(3):1915–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene. 2004;23(6):1308–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao H, Yang J, Fan T, Li S, Ren X. RhoE functions as a tumor suppressor in esophageal squamous cell carcinoma and modulates the PTEN/PI3K/Akt signaling pathway. Tumour Biol. 2012;33(5):1363–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Lu Z, Liu H, Xue L, Xu P, Gong T, Hou G. An activated Notch1 signaling pathway inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma cell line EC9706. Int J Oncol. 2008;32(3):643–51.PubMedGoogle Scholar
  28. 28.
    Xia J, Wang F, Wang L, Fan Q. Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-kappaB signaling pathway. Tumour Biol. 2013;34(1):317–28.CrossRefPubMedGoogle Scholar
  29. 29.
    Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, et al. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res. 2012;72(17):4405–16.CrossRefPubMedGoogle Scholar
  30. 30.
    Wu PP, Zou JH, Tang RN, Yao Y, You CZ. Detection and clinical significance of DLC1 gene methylation in serum DNA from colorectal cancer patients. Chin J Cancer Res. 2011;23(4):283–7.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Guan M, Tripathi V, Zhou X, Popescu NC. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Cancer Genet Ther. 2008;15(6):371–81.CrossRefGoogle Scholar
  32. 32.
    Guan CN, Zhang PW, Lou HQ, Liao XH, Chen BY. DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. Asian Pac J Cancer Prev. 2012;13(4):1231–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer. 2011;128(6):1393–403.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, et al. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 2006;59(9):947–51.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Jin Y, Tian X, Shang Y, Huang P. Inhibition of DLC-1 gene expression by RNA interference in the colon cancer LoVo cell line. Oncol Rep. 2008;19(3):669–74.PubMedGoogle Scholar
  36. 36.
    Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005;65(14):6042–53.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377(6549):539–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2(5):249–56.CrossRefPubMedGoogle Scholar
  39. 39.
    Cary LA, Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci. 1996;109(Pt 7):1787–94.PubMedGoogle Scholar
  40. 40.
    Bohm M, Totzeck B, Birchmeier W, Wieland I. Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis. 1994;12(1):55–62.CrossRefPubMedGoogle Scholar
  41. 41.
    Toyoyama H, Nuruki K, Ogawa H, Yanagi M, Matsumoto H, Nishijima H, et al. The reduced expression of e-cadherin, alpha-catenin and gamma-catenin but not beta-catenin in human lung cancer. Oncol Rep. 1999;6(1):81–5.PubMedGoogle Scholar
  42. 42.
    Ogata S, Takeuchi M, Okumura K, Taguchi H. Apoptosis induced by niacin-related compounds in HL-60 cells. Biosci Biotechnol Biochem. 1998;62(12):2351–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991;88(16):6961–5.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74(4):609–19.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Cailing Yang
    • 1
  • Dapeng Wu
    • 2
  • Jinling Jia
    • 2
  • Dong Liu
    • 3
  • Zhanguo Li
    • 3
  • Chunxiao Zhang
    • 4
  • Min Li
    • 3
  • Yonghua Xia
    • 3
  1. 1.Department of Oral and Maxillofacial SurgeryThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina
  2. 2.Department of Orthopedic SurgeryThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina
  3. 3.Department of DermatologyThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina
  4. 4.Department of TuberculosisThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina

Personalised recommendations